Cite
Vehreschild MJGT, Taori S, Goldenberg SD, et al. Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE). Eur J Clin Microbiol Infect Dis. 2019;38(1):199doi: 10.1007/s10096-018-3410-8.
Vehreschild, M. J. G. T., Taori, S., Goldenberg, S. D., Thalhammer, F., Bouza, E., van Oene, J., Wetherill, G., & Georgopali, A. (2019). Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE). European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 38(1), 199. https://doi.org/10.1007/s10096-018-3410-8
Vehreschild, Maria J G T, et al. "Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)." European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology vol. 38,1 (2019): 199. doi: https://doi.org/10.1007/s10096-018-3410-8
Vehreschild MJGT, Taori S, Goldenberg SD, Thalhammer F, Bouza E, van Oene J, Wetherill G, Georgopali A. Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE). Eur J Clin Microbiol Infect Dis. 2019 Jan;38(1):199. doi: 10.1007/s10096-018-3410-8. PMID: 30406879; PMCID: PMC6315086.
Copy
Download .nbib